Effects of Torilis japonica Extract on DNCB-induced Contact Dermatitis in BALB/c Mice = 사상자 추출물이 DNCB로 유도된 BALB/c 마우스의 접촉성 피부염에 미치는 효과

국문 초록 (Abstract)

목적: 본 연구에서는 TJ 열수추출물이 아토피 피부염에 미치는 효과를 확인하고자 하였다. 방법: 2, 4-dinitrochlorobenzen (DNCB)으로 BALB/c 마우스에 1차 감작 후 3주간 2차 감작을 시행하여 아토피 유사 피부병변을 나타내는 접촉성 피부염을 유발한 뒤 동결건조 처리된 TJ 분말을 (PBS/EtOH/Cremophor=6:1:3)에 용해시켜 쥐의 등 피부에 10, 50 mg/ml 농도로 3주간 도포하였다. 결과: TJ 열수추출물은 아토피 피부 병변의 염증세포 침윤을 억제하였고 (10, 50 mg/ml ) 표피와 진피 두께를 회복시켰으며 (10, 50 mg/ml ), 혈청에서 히스타민 방출을 억제하였다 (00 mg/ml ). 또한 Th2 세포와 관련된 cytokine인 interleukin (IL)-4, IL-5, IL-13과 thymic stromal lymphopoietin (TSLP)의 mRNA 발현 양을 감소시켰고 (10, 50 mg/ml ), Th2 chemokine인 thymus- and activation-regulated chemokine (TARC or CCL17)의 mRNA의 발현 양을 감소시켰다 (10, 50 mg/ml ). 결론: TJ 열수추출물을 BALB/c 마우스에 외용하였을 때 항아토피 효과가 있음을 확인하였으며 따라서 TJ가 아토피 피부염 치료의 외용제로 활용될 수 있을 것으로 사료된다.

참고문헌 (Reference)

1 구본석, "사상자(Torilis Fructus)가 섬유아세포의 Procollagen 생합성과Matrix metalloproteinase-I(MMP-1)의 활성에 미치는 영향" 한국생약학회 38 (38): 349-353, 2007

2 Kim GT, "Torilis japonica extract, a new potential EMT suppressor agent by regulation of EGFR signaling pathways" 45 (45): 1673-1679, 2014

3 Carr WW, "Topical calcineurin inhibitors for atopic dermatitis : review and treatment recommendations" 15 (15): 303-310, 2013

4 Sung YY, "Topical application of an ethanol extract prepared from illicium verum suppresses atopic dermatitis in NC/Nga mice" 144 : 151-159, 2012

5 Kakinuma T, "Thymus and activation-regulated chemokine in atopic dermatitis : Serum thymus and activationregulated chemokine level is closely related with disease activity" 107 (107): 535-541, 2001

6 Saeki H, "Thymus and activation regulated chemokine(TARC)/CCL17 and skin diseases" 43 (43): 75-84, 2006

7 Wang YH, "Thymic stromal lymphopoietin, OX40-ligand, and interleukin-25 in allergic responses" 39 (39): 798-806, 2009

8 Urb M, "The role of mast cells in the defence against pathogens" 8 (8): e1002619-, 2012

9 Amin K, "The role of mast cells in allergic inflammation" 106 (106): 9-14, 2012

10 Park SM, "The documentary examining of gynecologic symptoms and medical substances of fumigation treatment" Kyung-San University 2002

11 Galli SJ, "The development of allergic inflammation" 454 (454): 445-454, 2008

12 Moran TP, "The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch" 134 (134): S160-S161, 2014

13 Takai T, "TSLP expression induced via Toll-like receptor pathways in human keratinocytes" 535 : 371-387, 2014

14 Akdis CA, "T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis" 113 (113): 628-634, 1999

15 Stanbury RM, "Systemic corticosteroid therapy--side effects and their management" 82 (82): 704-708, 1998

16 Yoo J, "Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin" 202 (202): 541-549, 2005

17 Izuhara K, "Signal transduction via the interleukin-4 receptor and its correlation with atopy" 3 (3): 3-10, 1999

18 Hijnen D, "Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cellattracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis" 113 (113): 334-340, 2004

19 Tazawa T, "Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis" 295 (295): 459-464, 2004

20 Sher A, "Regulation of immunity to parasites by T cells and T cell-derived cytokines" 10 : 385-409, 1992

21 Park SJ, "Platycodon grandiflorus alleviates DNCBinduced atopy-like dermatitis in NC/Nga mice" 44 (44): 469-474, 2012

22 Vestergaard C, "Overproduction of Th2-specific chemokines in NC/Nga mice exhibiting atopic dermatitis-like lesions" 104 (104): 1097-1105, 1999

23 Yamazaki F, "Overactivation of IL-4-induced activator protein-1 in atopic dermatitis" 28 (28): 227-233, 2002

24 Leung DY, "New insights into atopic dermatitis" 113 (113): 651-657, 2004

25 Guttman-Yassky E, "New era of biologic therapeutics in atopic dermatitis" 13 (13): 549-561, 2013

26 Kalesnikoff J, "New developments in mast cell biology" 9 (9): 1215-1223, 2008

27 Kabashima K, "New concept of the pathogenesis of atopic dermatitis : interplay among the barrier, allergy, and pruritus as a trinity" 70 (70): 3-11, 2013

28 Takeda K, "Mouse models of allergic diseases" 21 : 660-665, 2009

29 Ackerman SJ, "Mechanisms of eosinophilia in the pathogenesis of hypereosinophilic disorders" 27 (27): 357-375, 2007

30 Weller K, "Mast cells are required for normal healing of skin wounds in mice" 20 (20): 2366-2368, 2006

31 Lindstedt KA, "Isolation of mast cell granules" 3 (3): 16-, 2006

32 Hasbold J, "Integrating signals from IFN-gamma and IL-4by B cells : positive and negative effects on CD40 ligand-induced proliferation, survival, and division-linked isotype switching to IgG1, IgE and IgG2a" 163 (163): 4175-4181, 1999

33 Jung M, "Inhibitory effect of 5, 6-dihydroergosteol-glucoside on atopic dermatitis-like skin lesions via suppression of NF-kappaB and STAT activation" 79 (79): 252-261, 2015

34 Corren J, "Inhibition of interleukin-5 for the treatment of eosinophilic diseases" 13 (13): 305-312, 2012

35 Onoue A, "Induction of eosinophil-and Th2-attracting epidermal chemokines and cutaneous late-phase reaction in tape-stripped skin" 18 (18): 1036-1043, 2009

36 Alysandratos KD, "Increased affected skin gene expression and serum levels of thymic stromal lymphopoietin in atopic dermatitis" 105 (105): 403-404, 2010

37 Hamid Q, "In vivo expression of IL-12 and IL-13 in atopic dermatitis" 98 (98): 225-231, 1996

38 Romagnani S, "Immunologic influences on allergy and the TH1/TH2 balance" 113 (113): 395-400, 2004

39 Liu FT, "IgE, mast cells, and eosinophils in atopic dermatitis" 41 (41): 298-310, 2011

40 Galli SJ, "IgE and mast cells in allergic disease" 18 (18): 693-704, 2012

41 Hamelmann E, "IL-5-induced airway eosinophilia--the key to asthma?" 179 : 182-191, 2001

42 Kouro T, "IL-5-and eosinophil-mediated inflammation : from discovery to therapy" 21 (21): 1303-1309, 2009

43 Oh MH, "IL-13 induces skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin" 186 (186): 7232-7242, 2011

44 Soumelis V, "Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP" 3 (3): 673-680, 2002

45 Gschwandtner M, "Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model" 68 (68): 37-47, 2013

46 College of Oriental Medicine Compilation Committee of Herbalogy, "Herbalogy" Younglimsa 630-631, 2006

47 Simon D, "Eosinophils and atopic dermatitis" 59 (59): 561-570, 2004

48 Wang IJ, "Environmental risk factors for early infantile atopic dermatitis" 18 (18): 441-447, 2007

49 Imaizumi A, "Effective treatment of pruritus in atopic dermatitis using H1antihistamines(second-generation antihistamines) : changes in blood histamine and tryptase levels" 33 (33): 23-29, 2003

50 Sin MG, "Clinical Herbalogy" Younglimsa 197-, 1994

51 Sone K, "Changes of estrous cycles with aging in female F344/n rats" 56 (56): 139-148, 2007

52 Segal AO, "CSACI position statement : safety of topical calcineurin inhibitors in the management of atopic dermatitis in children and adults" 9 (9): 24-, 2013

53 Shimada Y, "Both Th2and Th1 chemokines(TARC/CCL17, MDC/CCL22, and Mig/CXCL9)are elevated in sera from patients with atopic dermatitis" 34 (34): 201-208, 2004

54 Nutten S, "Atopic dermatitis: global epidemiology and risk factors" 66 (66): 8-16, 2015

55 Correale CE, "Atopic dermatitis: a review of diagnosis and treatment" 60 (60): 1191-1198, 1999

56 Gittler JK, "Atopic dermatitis results in intrinsic barrier and immune abnormalities : implications for contact dermatitis" 131 : 300-313, 2013

57 Boguniewicz M, "Atopic dermatitis : a disease of altered skin barrier and immune dysregulation" 242 (242): 233-246, 2011

58 Leung DY, "Atopic dermatitis" 361 (361): 151-160, 2003

59 Cho WI, "Antimicrobial activity of torilin isolated from Torilis japonica fruit against Bacillus subtilis" 73 (73): 37-46, 2008

60 Herman SM, "Antihistamines in the treatment of dermatitis" 7 (7): 467-473, 2003

61 Greaves MW, "Antihistamines in dermatology" 18 (18): 220-229, 2005

62 Kim MS, "Anti-invasive activity of torilin, a sesquiterpene compound isolated from Torilis japonica" 8 (8): 359-364, 2001

63 Corren J, "Anti-interleukin-5 antibody therapy in asthma and allergies" 11 (11): 565-570, 2011

64 Choi JE, "Anti-inflammatory and Antioxidant Effects of Water Extracts of Sasangja-tang(SSJ) and Gami-sasangja-tang (GSJ)." 23 (23): 7-8, 2015

65 Kim SM, "Anti-inflammatory activities of Torilis japonica fruit" 29 (29): 384-390, 1998

66 Kim MS, "Anti-angiogenic activity of torilin, a sesquiterpene compound isolated from Torilis japonica" 87 (87): 269-275, 2000

67 Stein ML, "Anti-IL-5(mepolizumab)therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels" 121 (121): 1473-1483, 2008

68 Fonacier LS, "Allergic skin diseases" 125 (125): S138-S149, 2010

69 Kimber L, "Allergic contact dermatitis" 2 (2): 201-211, 2002

70 Petersen LJ, "Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique : characterization of factors influencing histamine releasability" 97 (97): 672-679, 1996

71 Minami K, "A chronic model for evaluating the itching associated with allergic conjunctivitis in rats" 4 (4): 101-108, 2004